Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 3.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,228 shares of the company’s stock after selling 223 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Revolution Medicines were worth $328,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Revolution Medicines by 65.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 32,127 shares of the company’s stock worth $1,457,000 after purchasing an additional 12,744 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Revolution Medicines by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,041 shares of the company’s stock worth $267,000 after purchasing an additional 1,115 shares during the period. Values First Advisors Inc. acquired a new stake in Revolution Medicines in the third quarter worth about $93,000. Allspring Global Investments Holdings LLC lifted its holdings in Revolution Medicines by 1,109.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,589 shares of the company’s stock worth $1,750,000 after purchasing an additional 35,399 shares during the period. Finally, Raymond James & Associates lifted its holdings in Revolution Medicines by 156.2% in the 3rd quarter. Raymond James & Associates now owns 190,505 shares of the company’s stock valued at $8,639,000 after acquiring an additional 116,135 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Buying and Selling

In related news, COO Margaret A. Horn sold 50,000 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $50.34, for a total value of $2,517,000.00. Following the transaction, the chief operating officer now owns 132,320 shares in the company, valued at approximately $6,660,988.80. This represents a 27.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mark A. Goldsmith sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $44.93, for a total value of $449,300.00. Following the completion of the transaction, the insider now owns 300,170 shares in the company, valued at $13,486,638.10. This represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 127,866 shares of company stock worth $6,355,624. Insiders own 8.00% of the company’s stock.

Analysts Set New Price Targets

RVMD has been the subject of a number of research analyst reports. Barclays upped their price target on shares of Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, September 27th. Needham & Company LLC upped their price target on shares of Revolution Medicines from $61.00 to $68.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Wedbush reissued an “outperform” rating and issued a $59.00 price target on shares of Revolution Medicines in a report on Thursday, August 8th. JPMorgan Chase & Co. upped their price target on shares of Revolution Medicines from $54.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Guggenheim upped their price target on shares of Revolution Medicines from $72.00 to $82.00 and gave the company a “buy” rating in a report on Monday, October 28th. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $61.00.

Revolution Medicines Trading Down 3.9 %

RVMD stock opened at $55.13 on Monday. Revolution Medicines, Inc. has a one year low of $20.51 and a one year high of $62.40. The firm has a market capitalization of $9.27 billion, a PE ratio of -15.36 and a beta of 1.40. The firm has a 50-day moving average of $49.14 and a two-hundred day moving average of $44.02.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). During the same quarter in the prior year, the firm earned ($0.99) EPS. On average, equities research analysts anticipate that Revolution Medicines, Inc. will post -3.51 earnings per share for the current year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.